Ovarian cancer drug olaparib ‘can delay disease in newly diagnosed’
A drug for advanced ovarian cancer has been approved for use in newly diagnosed patients in England, after a trial showed it could delay progression of the disease for three years. Up to 600 women with a hereditary type of the disease could benefit each year. Health bosses said olaparib had the potential to make… Read More »